ライフサイエンスコーパス: long acting beta(2) agonist

1 ed to high-dose inhaled corticosteroids plus long-acting beta2 agonists.

2 c despite taking inhaled corticosteroids and long-acting beta(2)-agonists.

3 g high doses of inhaled corticosteroids plus long-acting beta(2)-agonists.

4 79 [CI, 0.67 to 0.94]) but not compared with long-acting beta2-agonists alone (relative risk, 0.82 [C

5 The use of inhaled long-acting beta2-agonists alone is not appropriate.

6 offer insights into the mechanisms by which long-acting beta(2)-agonists and glucocorticoids might r

7 Because inhaled long-acting beta2 agonists and corticosteroid combinatio

8 d on inhaled corticosteroids with or without long-acting beta2-agonists and in patients with COPD wit

9 dysplasia and exposure to the combination of long-acting beta2-agonists and inhaled corticosteroids (

10 for renal dysplasia associated with combined long-acting beta2-agonists and inhaled corticosteroids.

11 aler therapy with an inhaled corticosteroid, long-acting beta2-agonist, and long-acting muscarinic an

12 Long-acting beta(2)-agonists are prescribed for patients

13 n inhalers that contain a corticosteroid and long-acting beta(2)-agonist as reliever therapy in addit

14 Use of long-acting beta2-agonists before achieving a reduction

15 -severe asthma on inhaled corticosteroid and long-acting beta(2)-agonist but not maintenance oral cor

16 Treatment with long-acting beta2 agonists can reduce but not eliminate

17 Long-acting beta2-agonists can also increase steroid res

18 nts with COPD from an inhaled corticosteroid/long-acting beta2-agonist combination treatment to tripl

19 responsiveness to an inhaled corticosteroid/long-acting beta2-agonist combination versus a long-acti

20 Inhaled corticosteroids and long-acting beta2-agonist combinations are more effectiv

21 corticosteroids (ICS) or low-dosage ICS plus long-acting beta2 agonist fixed-combination therapy at s

22 o 7 (maximum 14) days inhaled corticosteroid/long-acting beta2-agonist fluticasone furoate/vilanterol

23 The long-acting beta(2)-agonist formoterol and the glucocort

24 hort-acting beta2-agonist albuterol, and the long-acting beta2-agonists formoterol and olodaterol.

25 to high-dosage inhaled corticosteroids plus long-acting beta(2)-agonists (ICS plus LABA) and a histo

26 S) and inhaled corticosteroids combined with long-acting beta2-agonist (ICS/LABA) are standard treatm

27 e on high-dosage inhaled corticosteroids and long-acting beta2-agonists (ICS plus LABA) in the previo

28 Inhaled long-acting beta(2)-agonists improve asthma control when

29 Inhaled long-acting beta2 agonists improve lung function and hea

30 ycopyrrolate), a fixed-dose combination of a long-acting beta2-agonist (indacaterol) and a long-actin

31 l/glycopyrronium 110/50 mug with twice-daily long-acting beta2-agonist/inhaled corticosteroid salmete

32 -to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist, irrespective of baseline eosi

33 erapy, including inhaled corticosteroids and long-acting beta2-agonists, is effective in patients for

34 costeroid (ICS) fluticasone furoate (FF) and long-acting beta(2) -agonist (LABA) vilanterol (VI) on e

35 eceptor antagonist (LTRA step-up therapy) or long-acting beta(2)-agonist (LABA step-up therapy).

36 ids (ICSs) are insufficient include adding a long-acting beta(2)-agonist (LABA) or increasing the ICS

37 erapy with dual inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) therapy in patients wit

38 Long-acting beta2-agonists (LABA) and leukotriene recept

39 Long-acting beta2-agonists (LABA) were shown to inhibit

40 Inhaled corticosteroids (ICS) and long-acting beta(2)-agonists (LABAs) are recommended in

41 umulating for the efficacy of adding inhaled long-acting beta(2)-agonists (LABAs) to corticosteroids

42 Combination inhaled therapy with long-acting beta2 agonists (LABAs) and corticosteroids i

43 Safety concerns associated with long-acting beta2-agonists (LABAs) have led to many US F

44 OPD and treated with inhaled corticosteroid, long-acting beta2 agonist, long-acting muscarinic antago

45 cerbations) study, which compared once-daily long-acting beta2-agonist/long-acting muscarinic antagon

46 ng-acting beta2-agonist combination versus a long-acting beta2-agonist/long-acting muscarinic antagon

47 Leukotriene receptor antagonists and long-acting beta2-agonists may allow for reduction of in

48 ugh there is still controversy as to whether long-acting beta2-agonists may increase the risk of asth

49 = 7), long-acting anticholinergics (n = 10), long-acting beta2-agonists (n = 22), corticosteroids (n

50 tment (high-dose inhaled corticosteroids and long-acting beta2-agonists or medium- to high-dose inhal

51 reas the reduction in airway eosinophilia by long-acting beta(2)-agonists probably operates through a

52 nary disease (COPD) and, in combination with long-acting beta2 agonists, reduce exacerbations and imp

53 Inhaled corticosteroids plus long-acting beta2-agonists reduced deaths in relative te

54 -to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist require additional treatment o

55 rolled, crossover study of the effect of the long-acting beta(2)-agonist salmeterol on airway inflamm

56 tested the hypothesis that inhaled combined long-acting beta2-agonist (salmeterol) and corticosteroi

57 fluticasone propionate (F), with an inhaled long-acting beta(2)-agonist, salmeterol (S), to treat th

58 d that higher doses of inhaled steroids with long-acting beta2 agonists should be used for total cont

59 in addition to inhaled corticosteroids plus long-acting beta2-agonist therapy could improve the live

60 erapy with fixed-dose inhaled corticosteroid/long-acting beta2-agonist therapy was analyzed.

61 r without a leukotriene receptor antagonist; long-acting beta2-agonist therapy was not permitted duri

62 vious 12 months, with adjustment for ICS and long-acting beta(2)-agonists use (odds ratio, 2.7; 95% c

63 The LOB that occurs with chronic long-acting beta2-agonists use is not affected by ADRB2

64 -to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist were eligible for participatio

65 roids combined with oral corticosteroids and long-acting beta2-agonists) were extracted from 65 Dutch

66 Salmeterol is a long-acting beta2-agonist, widely used as an inhaled tre

67 s year, and receiving inhaled corticosteroid/long-acting beta2-agonist with or without LAMA daily for